Who knows. Love another chance to buy sub 2. Sold > 220 just because it has a tendency to retrace on light volume. 20 x 11 eps seemed about right. Next year shows a larger rise to nearer 13. Then 250-260 range once the acquisition rationale and synergies have been proven. IMHO. |
A great trading statement from AMS earlier this month, the share price bounced to around 228p from 190p now falling back why I asked myself??? |
Good TU , but I expected a bigger bounce considering recent slide. Small company results often take a bit longer to hit the analysts desks I think , hoping for a bit more recovery in the next week. Still 20% underwater myself and have rather a lot... |
Yes indeed elsa7878. AMS`s turnover is massive with a good profit margin I would feel the dividend will be increased IMHO. |
Excellent and highly encouraging update. |
A positive trading statement including a mention i.e. takeover rumours of last year would help the share price IMHO. |
Just say it's made in Israel. |
Are US tariffs likely to be a problem for liquiband? |
Time to get off AIM and get a main listing ? Expecting a trading statement soon, so will soon know how the deal is going. |
Hopefully the tide has turned |
Probably more related to the widespread heavy fall of UK AIM 50 shares since Xmas |
Hoping that the price drop off late is not due to bad news on the horizon? |
It would seem that the takeover rumours were unsubstantiated. We could do with some positive product news IMHO. |
Octopus investments purchased a million+ shares on 30/10/24 and a good rise today. |
Given the budget , volume not surprising, and clearly the issue is IHT not a bid sadly. |
Some unusual volume here in last three trading days. Nearly 4 times as many trades today as normal |
Is there a bid coming? |
Not enough clearly. |
Always good to see Directors buying:-Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that it was notified on 10 October 2024 that on the same day Grahame Cook, Non-Executive Director, purchased 48,864 ordinary shares of 5p each ("Ordinary Shares") at a price of 205.25p per Ordinary Share. |
Maybe it's time to go for a full listing on the main market. With the aim, in due course of getting into the FTSE 250. |
I cannot understand why AMS cannot give out a statement denying the rumours. |
Have been watching AMS after their interims and it's an odd one. There was the (clearly false) rumour of bid interest from buyout firm Inflexion "and others". But looking at the numbers from the acquisition of Peters Surgical, they had sales of €84m to y/e of 31/12/23 with expected growth of 4% this year. That coincides with AMS's y/e date so the completion of the acquisition on 1/7/24 is timed to coincide with the 1H point.
AMS's 1H rev was £68m, and €84m+4% = around £73m.
Doing the linear extrapolation implies the FY outturn for AMS would be rev of 2 x £68 + 73/2 = £172m.
SharePad forecasts are £178.4m so it's about right.
Maybe this is a high-probability entry point, or maybe something's up that the market seems to be indicating, albeit on low volume. Normally talk of one or more buyout firms circling would be more supportive of the share price, and the fact that a specific one - Inflexion - was named would make a false ramp unlikely. |
needs to find support soon or it could head to 180, latest rns all looked great |
Chart looking difficult to have any confident view but currently I keep watching a drop to around 216. The high rise recently must have been based on news not rumour, I will keep my hand in my pockets and my no talking continuing, I suspect another fall below 216 and then another reversal. |
I felt that the increase in the share price was over done due to the rumours in the city involving AMS possibly talking to interested buyout investment Companies. The robust results from AMS plus the dividend increase of 10% will steady things down hopefully to around 250p. IMHO AMS are worth considerably more than today closing price. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
